- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07944560
Development of dEep EndometrioSis Following Acute haemoPerITonEum (DEESPITE)
This study investigates whether acute pelvic pain with haemoperitoneum is associated with an increased risk of developing deep pelvic endometriosis, compared with acute pelvic pain without haemoperitoneum. Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to a single follow-up visit, including a transvaginal ultrasound and validated questionnaires.
Study Overview
Status
Conditions
Detailed Description
This is a single-centre, non-pharmacological, interventional, no-profit study conducted at the Obstetric-Gynecological Emergency Department and the Infertility Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to participate. Cases are women with documented haemoperitoneum and no previous diagnosis of endometriosis. Controls are women with acute pelvic pain without haemoperitoneum and no previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year). Women with previous hysterectomy or oophorectomy, or established menopause, are excluded.
Participants who provide informed consent will attend a single follow-up visit, lasting approximately one hour. The visit includes a second-level transvaginal ultrasound to identify lesions suggestive of deep endometriosis according to the IDEA criteria, and validated questionnaires assessing quality of life (SF-12), endometriosis-specific quality of life (EHP-30), sexual function (FSFI) and pain (NRS).
The primary outcome is the incidence of sonographically diagnosed deep pelvic endometriosis between 6 months and up to 5 years after the acute event, comparing cases and controls. Secondary outcomes include the impact of the acute event on chronic pelvic pain and quality of life, and the association between treatment of the acute event (surgical vs conservative) or use of hormonal therapy during follow-up and the development of endometriosis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Edgardo Somigliana, PhD
- Phone Number: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
Study Contact Backup
- Name: Marco Reschini, MSc
- Phone Number: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
Study Locations
-
-
MI
-
Milan, MI, Italy, 20122
- Recruiting
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contact:
- Edgardo Somigliana, PhD
- Phone Number: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
-
Contact:
- Marco Reschini, MSc
- Phone Number: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024
Description
Inclusion Criteria:
- Women aged 18-50 years
- Female sex
- Attendance at the Obstetric-Gynecological Emergency Department (Clinica Mangiagalli) for acute pelvic pain
- For cases: documented haemoperitoneum without a previous diagnosis of endometriosis
- For controls: no documented haemoperitoneum without a previous diagnosis of endometriosis
Exclusion Criteria:
- Previous hysterectomy and/or oophorectomy
- Established menopause
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Haemoperitoneum
Women aged 18-50 with acute pelvic pain and documented haemoperitoneum, without a previous diagnosis of endometriosis |
|
No haemoperitoneum
Women aged 18-50 with acute pelvic pain and no documented haemoperitoneum, without a previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of sonographically diagnosed deep pelvic endometriosis
Time Frame: From 6 months up to 5 years after the acute event
|
Incidence of deep pelvic endometriosis diagnosed by second-level transvaginal ultrasound according to IDEA criteria, comparing cases (haemoperitoneum) and controls (no haemoperitoneum) |
From 6 months up to 5 years after the acute event
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pelvic pain intensity assessed using the Numeric Rating Scale (NRS)
Time Frame: From 6 months up to 5 years after the acute event
|
Comparison of pelvic pain intensity between participants with and without haemoperitoneum at the index acute event, assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity. |
From 6 months up to 5 years after the acute event
|
|
Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30)
Time Frame: From 6 months up to 5 years after the acute event
|
Comparison of the Endometriosis Health Profile-30 (EHP-30) overall summary score between participants with and without haemoperitoneum at the index acute event. The core questionnaire contains 30 items, each scored from 0 to 4. A single overall score is calculated by summing the scores of all 30 items, dividing the sum by the maximum possible score of 120, and multiplying by 100. The overall score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Quality of life assessed using the Short Form Health Survey (SF-12)
Time Frame: From 6 months up to 5 years after the acute event
|
Comparison of the 12-Item Short Form Health Survey (SF-12) scores between participants with and without haemoperitoneum at the index acute event. Scores will be calculated using the questionnaire's standard scoring algorithm. Norm-based scores have a reference population mean of 50 and a standard deviation of 10, with higher scores indicating better physical health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Sexual function assessed using the Female Sexual Function Index (FSFI)
Time Frame: From 6 months up to 5 years after the acute event
|
Comparison of Female Sexual Function Index (FSFI) total scores between participants with and without haemoperitoneum at the index acute event. The FSFI is a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Weighted domain scores are summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function. |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to initial treatment
Time Frame: From 6 months up to 5 years after the acute event
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants initially managed surgically with those managed conservatively. Initial treatment will be classified from medical records. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to hormonal therapy use
Time Frame: From 6 months up to 5 years after the index acute event.
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants who received hormonal therapy during follow-up with those who did not. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the index acute event.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pain
- Neurologic Manifestations
- Pathologic Processes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Digestive System Diseases
- Genital Diseases, Female
- Hemorrhage
- Peritoneal Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Endometriosis
- Pelvic Pain
- Hemoperitoneum
Other Study ID Numbers
- PMA2025_02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.